NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Is Up 13.6% After Strong Taletrectinib Brain Metastases Data at IASLC 2025
Nuvation Bio recently announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies of IBTROZI™ (taletrectinib) in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, featuring impressive objective response rates and progression-free survival data shared at the IASLC 2025 World Conference on Lung Cancer in Barcelona.
An especially significant insight is the strong intracranial response rate observed among patients with brain...